Aligos Therapeutics, Inc. (ALGS)
 NASDAQ: ALGS · Real-Time Price · USD
 8.20
 -0.41 (-4.76%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $965.00K in the quarter ending June 30, 2025, a decrease of -9.05%. This brings the company's revenue in the last twelve months to $3.17M, down -60.16% year-over-year. In the year 2024, Aligos Therapeutics had annual revenue of $3.95M, down -74.60%.
Revenue (ttm) 
 $3.17M
Revenue Growth 
 -60.16%
P/S Ratio 
 20.23
Revenue / Employee 
 $45,343
Employees 
 70
Market Cap 
50.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 3.95M | -11.58M | -74.60% | 
| Dec 31, 2023 | 15.53M | 1.62M | 11.66% | 
| Dec 31, 2022 | 13.91M | 9.55M | 219.04% | 
| Dec 31, 2021 | 4.36M | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
ALGS News
- 22 hours ago - Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 13 days ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 - GlobeNewsWire
- 16 days ago - Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference - GlobeNewsWire
- 23 days ago - Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - GlobeNewsWire
- 2 months ago - Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - GlobeNewsWire